Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thorough QT Study of Telotristat Etiprate
NCT02155205Phase 1Completed
- Sponsor
- Lexicon Pharmaceuticals, Inc.
- Start
- May 2014
- Primary completion
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of telotristat ethyl in Carcinoid Syndrome (CS) (3 arms), sponsored by Lexicon Pharmaceuticals, Inc. Primary endpoint: QT interval corrected for heart rate. Started May 2014; status: completed.
02
Drugs
telotristat ethyl
03
Conditions
Carcinoid Syndrome (CS)
Beyond the preview
Go deeper on NCT02155205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02155205.